scholarly journals GROUNDS FOR CIVIL LEGAL BIOBANKING RELATIONS AND STEM CELL DONATION

Author(s):  
D.V. Kinash
Keyword(s):  
Author(s):  
Ke Yan ◽  
Gang Zhang ◽  
Guoqiang Zhao ◽  
Baosong Liu ◽  
Jun Lu

The loss of hematopoietic stem cell donation (HSCD) volunteers is widespread worldwide. This study analyzed the distribution characteristics of volunteer retention between the swab sampling approach and blood sampling approach. The Shanghai branch of the China Bone Marrow Donation Program conducted a telephone follow-up with 18,963 volunteers to understand volunteer retention. Multiple logistic regression was used to analyze the distribution characteristics of volunteer retention between two different sampling approaches, and a forest plot was used to observe the distribution trend. Only 32.37% of the volunteers could be contacted, and the loss of volunteers was severe. The volunteer retention is influenced by sampling approaches and demographic characteristics, and Shanghai natives, the highly educated, and students had better retention. The volunteer retention of the swab group was better among young people and technicians, while the volunteer retention of the blood sample group was lower among public officials and workers, and the volunteer retention in the blood sample group was more significantly affected by changes in population characteristics. To enhance the stability of volunteers, managers should improve the contact channels and frequency, expand the ratio of stable volunteers, strengthen volunteer education in the process of collecting blood samples, and respect individuals’ willingness.


Author(s):  
Thilo Mengling ◽  
Gabi Rall ◽  
Stefanie N. Bernas ◽  
Nadia Astreou ◽  
Sandra Bochert ◽  
...  

AbstractThe COVID-19 pandemic has serious implications also for patients with other diseases. Here, we describe the effects of the pandemic on unrelated hematopoietic stem cell donation and transplantation from the perspective of DKMS, a large international donor registry. Especially, we cover the development of PBSC and bone marrow collection figures, donor management including Health and Availability Check (HAC), transport and cryopreservation of stem cell products, donor recruitment and business continuity measures. The total number of stem cell products provided declined by around 15% during the crisis with a particularly strong decrease in bone marrow products. We modified donor management processes to ensure donor and product safety. HAC instead of confirmatory typing was helpful especially in countries with strict lockdowns. New transport modes were developed so that stem cell products could be safely delivered despite COVID-19-related travel restrictions. Cryopreservation of stem cell products became the new temporary standard during the pandemic to minimize risks related to transport logistics and donor availability. However, many products from unrelated donors will never be transfused. DKMS discontinued public offline donor recruitment, leading to a 40% decline in new donors during the crisis. Most DKMS employees worked from home to ensure business continuity during the crisis.


Author(s):  
Miok Kim ◽  
Minho Shin

This study explored how an educational program on hematopoietic stem-cell donation (HSCD) affects the knowledge, attitude, and willingness for HSCD among nursing students. The subjects were the nursing students at a university in Korea: 43 in the experimental group and 42 in the control group. All subjects took a pre-test, and only the experimental group attended an educational program. Both the groups completed two post-tests. Variables of interest were knowledge, attitude, willingness, and registration ratio for HSCD. The educational program increased knowledge (F = 8.093, p < 0.001) and attitude (F = −6.422, p < 0.001) of the experiment group. After the program, the experimental group showed higher willingness for HSCD (χ2 = 7.609, p = 0.006) and higher registration ratio for HSCD (χ 2= 4.258, p = 0.039) compared to the control group. The educational programs for knowledge and attitude about HSCD will affect the students’ future nursing, and influence clients and their families toward positive perception on HSCD and organ donations.


Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 3276-3276 ◽  
Author(s):  
Jörg Halter ◽  
Yoshihisa Kodera ◽  
Alvaro Urbano Ispizua ◽  
Hildegard Greinix ◽  
Norbert Schmitz ◽  
...  

Abstract The risk for donors of allogeneic hematopoietic stem cells (HSC) by bone marrow (BM) or by peripheral blood (PB) harvest is generally considered negligible. Scattered reports of severe to life-threatening complications and a recent controversy on hematopoietic malignancies after GCSF administration for peripheral stem cell donation have challenged this opinion. Previous studies were limited by small numbers. In two consecutive retrospective surveys conducted in 2003 and 2006 amongst 338 allogeneic transplant centres from 38 European countries participating in the annual EBMT activity surveys, centres were asked to report all donor deaths, all severe adverse events (SAE’s), defined as occurring within 30 days and any hematological malignancy in a donor occurring after HSC donation. 262/338 teams (77.5%) responded to the first survey (1993–2002) and 169/262 (65%) centres replied to the second survey (2003–2005). The responding teams performed a total of 51’024 first allogeneic HSCT, 27’770 BM and 23’254 PB HSCT, which corresponds to 69% of all 73’947 first allogeneic HSCT reported during this time to EBMT. There were 5 donor deaths, 1 after BM and 4 after PB donation, an incidence of 0.98 per 10’000 donations (95% CI 0.32–2.29), 37 SAE’s (incidence 7.25/10’000 donations; 95% CI 5.11–9.99), 12 in BM (incidence 4.32/10000 donations; 95% CI 2.24–7.75) and 25 in PB donors (incidence 10.76/10’000 donations; 95% CI 6.97–15.85; p<0.02). In absolute numbers, there were 20 hematological malignancies occurring in donors (3.92/10’000 donations; 95% CI 2.39–6.05), 8 after BM (2.88/10’000 donations; 95% CI 1.24–5.68) and 12 after PB donation (5.16/10’000 donations; 95% CI 2.67–9.02; p = 0.3). Based on the different observation times, the incidence rates for developing hematological malignancies are 0.398 per 10’000 person-years for BM and 1.20 per 10’000 person-years for PB donation, resulting in a relative risk of 3.02 (95% CI 1.11–6.87, p=0.027). These data document a definitive risk for death, SAE’s and hematological malignancies with HSC donation. Deaths occur with similar frequency in both groups. SAE’s were more frequently reported after PB donation. The incidence rate for developing hematopoietic malignancies is higher after PB donation. These data clarify the recent controversy on HSC donation. They form a basis for donor counselling and underline the need for standardised donor follow up and international cooperation in order to define risk factors and to build up preventive measures.


Blood ◽  
2014 ◽  
Vol 124 (21) ◽  
pp. 2456-2456 ◽  
Author(s):  
Mark A Fiala ◽  
Soo Park ◽  
Camille N. Abboud ◽  
Amanda F. Cashen ◽  
Meagan Jacoby ◽  
...  

Abstract Background: Over the past two decades, peripheral blood stem cells (PBSC) have surpassed bone marrow as the preferred graft source for adult allogeneic transplantation due to its more rapid engraftment and potentially better graft-vs-tumor effects, and because PBSC collection is much less invasive for the donor. The optimal CD34+ PBSC dose is ≥ 4.0x106cells/kg, but doses ≥ 8.0x106cells/kg are suggested by some for reduced-intensity conditioning and haploidentical transplants. There is no established minimum CD34+ PBSC dose, but doses below 2.0x106cells/kg have been associated with a higher risk of engraftment delay and failure. There is significant inter-donor variability in the ability to mobilize PBSCs. Several factors have been identified as predictors of PBSC mobilization in healthy donors including: gender, age, weight, body mass index (BMI), and blood counts before and after mobilization. The impact of the donor’s comorbidities on mobilization is currently unknown. Patients/Methods: We performed retrospective chart review of 488 consecutive adult patients who underwent apheresis for allogeneic stem cell donation at Washington University School of Medicine from 2006 through 2013. Patients who received any collection regimen other than 10mcg/kg of G-CSF daily with 20 liters (+/-10%) apheresis on Day 5 were excluded. Patients who had undergone a previous apheresis for stem cell donation were excluded. Univariate analysis was performed to identify predictors of CD34+ PBSC collection in a single apheresis. Variables analyzed were: gender; age; weight; BMI; donor-to-recipient weight ratio; pre and post-mobilization blood counts (white blood count [WBC], hematocrit, platelets, neutrophils, lymphocytes, and monocytes); pre-mobilization glucose and triglyceride levels; post-mobilization peripheral blood (PB) CD34+count; and medical history significant for hypertension, hyperlipidemia, or diabetes mellitus. Subsequently, a linear regression multivariate analysis was performed with all variables found to be significant in the univariate analysis. 2-tailed tests for significance were used throughout the analysis. Results: 304 patients met the eligibility criteria for analysis. The median age was 53 years (range 18-76), 90% were Caucasian, and 50% were male. The median number of CD34+ cells collected was 7.4 x106/kg (range 0.8-27.1). 97% (295) collected ≥ 2.0x106 CD34+cells/kg, 81% (247) collected ≥ 4.0x106 CD34+cells/kg, and 44% (134) collected ≥ 8.0x106 CD34+ cells/kg. Post-mobilization PB CD34+ count (r= 0.841, p <0.001) and donor-to-recipient weight ratio (r= 0.439, p <0.001) were the strongest correlates with CD34+ collection. Weak correlations were seen with post-mobilization neutrophils (r= 0.360, p <0.001), WBC (r= 0.353, p <0.001), and hematocrit (r= 0.207, p <0.001); weight (r=0.280, p <0.001); BMI (r= 0.229, p <0.001); and age (r= -0.207, p <0.001). Male donors collected 9.1x106 CD34+ cells/kg compared to 7.5 x106 CD34+ cells/kg for females, on average (p = 0.003). Hypertension, hyperlipidemia, and diabetes mellitus were not associated with Day 1 CD34+ collection. We performed a multivariate model with the variables: post-mobilization PB CD34+ count; donor-to-recipient weight ratio; gender; post mobilization neutrophil, WBC, and hematocrit; weight; BMI; and age. In this analysis, post-mobilization PB CD34+count, donor-to-recipient weight ratio, and age were all independently significant. Conclusion: After one apheresis, the majority (81%) of donors collected ≥ 4.0x106 CD34+ cells/kg, the optimal number of CD34+ cells for standard allogeneic transplant, but only 44% were able to collect ≥ 8.0x106, the suggested number of CD34+ cells for reduced-intensity or haploidentical transplants. As these reduced-intensity and haploidentical transplants increase in frequency, the need for more accurate predictors of CD34+cell collection will also increase. Donor-to-weight ratio could be a useful tool to stratify potential donors for reduced-intensity and haploidentical transplants. In this study, 63% of donors with a donor-to-recipient weight ratio > 1.0 collected ≥ 8.0x106 CD34+cells/kg, while only 20% of donors with a donor-to-recipient weight ratio ≤ 1.0 did. While gender, weight, and BMI have previously been reported as predictors for CD34+ collection, they potentially were just surrogates for donor-to-recipient weight ratio. Disclosures No relevant conflicts of interest to declare.


Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 5434-5434
Author(s):  
Warren Fingrut

Abstract Patients with a variety of blood cancers and metabolic diseases may require a stem cell transplant as part of their treatment. However, 70% of patients do not have a suitable genetic match in their family. Stem cell donor-databases are used to match potential unrelated donors to patients worldwide. In Canada, individuals aged 17-35 years can register as donors online or at a stem cell drive where they provide consent and a tissue sample (buccal-swab) for Human Leukocyte Antigen (HLA) allele typing. To date, no guidelines have been published to recommend a process for stem cell donor recruitment at drives. Here, I outline a Canadian approach to stem cell drive design, which features evidence-based strategies to identify and recruit the most-needed stem cell donors and to minimize donor ambivalence and withdrawal from the registry. This model of stem cell drive design includes five stations: pre-screening, informed consent, registration, swabbing, and reconciliation. Registrant confidentiality and privacy is maintained at each station, and quality control is emphasized throughout. Registrants are first pre-screened to ensure donor eligibility. Recruiters at the prescreening station target the most-needed stem cell donors according to the literature: young, healthy, and ethnically-diverse males. Non-optimal and ineligible registrants are redirected to help out in other ways. Recruiters then explain the principles of stem cell donation and educate registrants about the stem cell donation process. Next, registrants proceed to the informed consent station, which is designed to meet the requirements of the World Marrow Donor Association's suggested procedures for procurement of informed consent at time of recruitment (2003). Here, recruiters hand registrants an information pamphlet, and explain blood and marrow stem cell collection procedure diagrams. The risks of donation are outlined, and registrants are informed of their right to withdraw at any time and about donor and patient anonymity. Registrants are subsequently guided through registration, where they provide their contact/demographic information, complete a health questionnaire, and sign a consent form to join the registry. Recruiters at this station error check registrants' forms to ensure correct completion, and educate registrants about the data collection, storage, usage, and confidentiality. Following registration, registrants proceed to swabbing, where they swab their cheeks to provide a tissue/DNA sample. Recruiters at this station affix barcode stickers to each swab kit component. While registrants swab their cheeks, volunteers perform an informed consent checkpoint by asking registrants if they understand the donation process, the risks involved, and the right to withdraw at any time. Finally, registrants visit reconciliation, where their paperwork is error checked again, their understanding of the donation process is assessed a final time to verify informed consent, and their kit processed for shipping. In summary, the five-station approach to stem cell drive design outlined in this presentation represents a new model for effective stem cell donor recruitment. Figure 1. Figure 1. Disclosures No relevant conflicts of interest to declare.


2003 ◽  
Vol 76 (12) ◽  
pp. 1771
Author(s):  
Giovanni Conti ◽  
Maurizio Gaido ◽  
Alessandro Amore ◽  
Rosanna Coppo ◽  
Paola Saracco ◽  
...  

2003 ◽  
Vol 32 (9) ◽  
pp. 873-880 ◽  
Author(s):  
G Favre ◽  
◽  
M Beksaç ◽  
A Bacigalupo ◽  
T Ruutu ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document